Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Transition Therapeutics begins phase I TT-401 trial

Dec. 14, 2011

Repros Therapeutics reports topline data on Androxal in hypogonadism and type 2 diabetes

Dec. 14, 2011

Mochida out-licenses type 2 diabetes treatment candidates

Dec. 13, 2011

Gedeon Richter gains extended marketing rights for Esmya

Dec. 12, 2011

Unigene Laboratories regains worldwide rights to oral PTH program

Dec. 12, 2011

Nissan Chemical presents novel adiponectin receptor protein 1 agonists

Dec. 12, 2011

Metabolex announces results from arhalofenate/febuxostat combination study

Dec. 12, 2011

Merck & Co. discovers new PRCP inhibitors

Dec. 12, 2011

DM-199 increases C-peptide levels in animal model

Dec. 9, 2011

Novel GPR119 receptor agonists disclosed by Boehringer Ingelheim

Dec. 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...